What are the new drugs for the treatment of rheumatoid arthritis (RA)?
The newest drugs for the treatment of rheumatoid arthritis are the Janus kinase (JAK) inhibitors, which are FDA approved under the brand names Rinvoq, Olumiant, and Xeljanz.
Janus kinase (JAK) inhibitors work by blocking the activity of one or more of the Janus kinase enzymes (JAK1, JAK2, JAK3, TYK2) in the JAK-STAT signaling pathway, an intracellular pathway that plays a major role in the release of the pro-inflammatory cytokines that stimulate inflammation in rheumatoid arthritis.
Janus kinase (JAK) inhibitors are part of a wider group of drugs called DMARDs (Disease-Modifying Anti-Rheumatic Drugs). DMARDs work to slow the progression of joint damage in rheumatoid arthritis.
For more information on the treatment of rheumatoid arthritis, see Rheumatoid Arthritis: Symptoms, Diagnosis & Treatment Options
New Treatments for Rheumatoid Arthritis - Latest FDA Approvals
|Drug||Drug Class||Administration||Company||FDA Approved for RA||RA Indication||Other Indications|
|upadacitinib (Rinvoq)||Janus kinase (JAK) inhibitor||
oral extended-release tablets
|baricitinib (Olumiant)||Janus kinase (JAK) inhibitor||oral tablets once daily||Eli Lilly and Company||31-May-2018||
|sarilumab (Kevzara)||interleukin-6 (IL-6) receptor antagonist||
every 2 weeks
|Sanofi and Regeneron||22-May-2017||
|tofacitinib (Xeljanz XR)||Janus kinase (JAK) inhibitor||oral extended-release tablets once daily||Pfizer Inc.||23-Feb-2016||
|golimumab (Simponi Aria)||tumor necrosis factor (TNF) blocker||intravenous infusion at weeks 0 and 4, then every 8 weeks||Janssen Biotech, Inc.||18-Jul-2013||
|tofacitinib (Xeljanz)||Janus kinase (JAK) inhibitor||oral tablets twice daily||Pfizer Inc.||6-Nov-2012||
|tocilizumab (Actemra)||interleukin-6 (IL-6) receptor antagonist||
every 4 weeks
every 2 weeks, then every week
|certolizumab pegol (Cimzia)||tumor necrosis factor (TNF) blocker||subcutaneous injection at weeks 0, 2, and 4, then every 2-4 weeks||UCB, Inc.||13-May-2009||
|golimumab (Simponi)||tumor necrosis factor (TNF) blocker||
once a month
|Janssen Biotech, Inc.||24-Apr-2009||
|rituximab (Rituxan)||CD20-directed cytolytic antibody||intravenous infusion two infusions separated by 2 weeks (one course) every 24 weeks or based on clinical evaluation (not sooner than every 16 weeks)||Genentech, Inc.||28-Feb-2006||
|abatacept (Orencia)||selective T cell costimulation modulator||
intravenous infusion at 0, 2 and 4 weeks, then every 4 weeks
|Bristol-Myers Squibb Company||23-Dec-2005||
|adalimumab (Humira)||tumor necrosis factor (TNF) blocker||
every 2 weeks
|anakinra (Kineret)||interleukin-1 receptor antagonist||
|Swedish Orphan Biovitrum AB||14-Nov-2001||
|infliximab (Remicade)||tumor necrosis factor (TNF) blocker||intravenous infusion at 0, 2, and 6 weeks, then every 8 weeks||Janssen Biotech, Inc.||10-Nov-1999||
|etanercept (Enbrel)||tumor necrosis factor (TNF) blocker||
|leflunomide (Arava)||pyrimidine synthesis inhibitor||oral tablets once daily||sanofi-aventis U.S. LLC||10-Sep-1998||
The biosimilars for the tumor necrosis factor (TNF) blockers Humira, Remicade, and Enbrel are also FDA approved for the treatment of rheumatoid arthritis:
Humira (adalimumab) Biosimilars
- Amjevita (adalimumab-atto)
- Cyltezo (adalimumab-adbm)
- Hyrimoz (adalimumab-adaz)
- Hadlima (adalimumab-bwwd)
- Abrilada (adalimumab-afzb)
- Hulio (adalimumab-fkjp)
- Yusimry (adalimumab-aqvh)
- Idacio (adalimumab-aacf)
- Yuflyma (adalimumab-aaty)
Remicade (infliximab) Biosimilars
- Inflectra (infliximab-dyyb)
- Renflexis (infliximab-abda)
- Ixifi (infliximab-qbtx)
- Avsola (infliximab-axxq)
Enbrel (etanercept) Biosimilars
Related medical questions
- What happens when you stop taking Xeljanz?
- How long does Xeljanz take to work?
- Can I drink alcohol while taking Xeljanz?
- What is Xeljanz used for and is it a biologic?
- Does Xeljanz cause hair loss?
- Does Xeljanz cause weight gain?
- Can you take Xeljanz with antibiotics and antifungals?
- Does Xeljanz cause high blood pressure?
- Is Xeljanz approved for ankylosing spondylitis?
- Is Xeljanz an immunosuppressant?
- Who makes Xeljanz and where is it made?
Related support groups
- Xeljanz (20 questions, 33 members)
- Xeljanz XR (6 questions, 6 members)
- Rinvoq (3 questions, 10 members)
- Upadacitinib (2 questions, 3 members)
- Humira (65 questions, 366 members)
- Remicade (21 questions, 185 members)
- Enbrel (21 questions, 208 members)
- Rituxan (17 questions, 101 members)
- Rituximab (11 questions, 51 members)
- Adalimumab (11 questions, 13 members)
- Actemra (10 questions, 47 members)
- Etanercept (10 questions, 9 members)
- Infliximab (8 questions, 16 members)
- Cimzia (7 questions, 43 members)
- Amjevita (5 questions, 5 members)
- Orencia (5 questions, 49 members)
- Ixifi (4 questions, 3 members)
- Sarilumab (4 questions, 3 members)
- Erelzi (4 questions, 4 members)
- Kevzara (4 questions, 5 members)
- Avsola (4 questions, 3 members)
- Tocilizumab (4 questions, 8 members)
- Cyltezo (4 questions, 3 members)
- Renflexis (4 questions, 3 members)
- Inflectra (4 questions, 7 members)
- Hyrimoz (3 questions, 4 members)
- Simponi (3 questions, 43 members)
- Eticovo (3 questions, 3 members)
- Baricitinib (3 questions, 4 members)
- Tofacitinib (3 questions, 6 members)
- Olumiant (3 questions, 4 members)
- Leflunomide (3 questions, 32 members)
- Hulio (3 questions, 3 members)
- Humira Pen (2 questions, 19 members)
- Hadlima (2 questions, 3 members)
- Arava (2 questions, 36 members)
- Simponi Aria (1 questions, 8 members)
- Kineret (1 questions, 11 members)
- Golimumab (1 questions, 7 members)
- Anakinra (1 questions, 4 members)
- Certolizumab (1 questions, 4 members)
- Abatacept (1 questions, 3 members)
- Rheumatoid Arthritis (293 questions, 1,294 members)